Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib and Decitabine Intensified Conditioning Regimen for Patients With High Risk Hematological Malignancies Underwenting Allogeneic Stem Cell Transplantation

NCT04582604 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT04582604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04582604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib and Decitabine Intensified Conditioning Regimen for Patients With High Risk Hematological Malignancies Underwenting Allogeneic Stem Cell Transplantation
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 1, 2020
Completion date
September 30, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral blood stem cell transplantation